Travere Therapeutics (TVTX) Return on Equity (2012 - 2026)

Travere Therapeutics has reported Return on Equity for 15 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Equity changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Equity for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.05% in Q2 2024, with the low at 0.01% in Q1 2022.
• Historically, Return on Equity has averaged 0.01% across 5 years, with a median of 0.0% in 2025.
• Annual changes were most pronounced in 2024 — Return on Equity grew 5 bps — and 2025, when it slipped 5 bps.
• Travere Therapeutics' Return on Equity stood at 0.01% in 2022, then jumped by 49 bps to 0.01% in 2023, then slumped by 106 bps to 0.0% in 2024, then soared by 510 bps to 0.0% in 2025, then slipped by 14 bps to 0.0% in 2026.
• The last three Return on Equity figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.